humanized mice to study FcγR function (Q42202178)

18 October 2017

title

humanized mice to study FcγR function (English)

1 reference

18 October 2017

3

Jeffrey V Ravetch

1 reference

18 October 2017

1

Stylianos Bournazos

1 reference

18 October 2017

2

David J DiLillo

1 reference

18 October 2017

publication date

1 January 2014

1 reference

Current Topics in Microbiology and Immunology

18 October 2017

published in

1 reference

18 October 2017

volume

382

1 reference

18 October 2017

page(s)

237-248

1 reference

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Passive antibody therapy for infectious diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Therapeutic antibodies for autoimmunity and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

A genetically humanized mouse model for hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Molecular mechanisms of anaphylaxis: lessons from studies with murine models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Fc receptor but not complement binding is important in antibody protection against HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Reconstitution of human Fc gamma RIII cell type specificity in transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Fcgamma receptors: old friends and new family members

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Antibodies, Fc receptors and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

A mouse model for HIV-1 entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

Mouse model recapitulating human Fcγ receptor structural and functional diversity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-07911-0_11

10.1007/978-3-319-07911-0_11

31 March 2020

Identifiers

DOI

1 reference

18 October 2017

1 reference